N/A
Completed N=38
A Study on the Use of CorMatrix® ECM® for Femoral Arterial Reconstruction
Source: ClinicalTrials.gov NCT02418156 ↗Enrolled (actual)
38
Serious AEs
36.8%
Results posted
Feb 2020
Primary outcomePrimary: Device-Related Adverse Events — 0 Proportion of Participants that Experien
Summary
To gather information on the use of CorMatrix ECM for Vascular Repair in the reconstruction of the femoral artery.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Device-Related Adverse Events |
— | — |
Eligibility Criteria
Inclusion Criteria
- Subjects must be undergoing femoral arterial reconstruction with patch angioplasty closure
- Surgeon intends to use CorMatrix ECM per FDA cleared Indications for Use
- Subject possesses ability to provide informed consent
- Subject expresses understanding and willingness to fulfill all expected requirements of protocol
Exclusion Criteria
- Known sensitivity to porcine material
Data sourced from ClinicalTrials.gov (NCT02418156). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.